Previous Page Table Of Contents Next Page

110

IMMUNOHISTOCHEMICAL ANALYSIS SUGGESTS THAT ACUTE REJECTION OF MURINE CARDIAC ALLOGRAFTS LACKING DONOR-TYPE APCs PROCEEDS VIA THE INDIRECT PATHWAY

Background: Although graft resident, bone marrow-derived antigen presenting cells (APCs) are highly immunogenic, they are not required for rejection, as chimeric BALB/c hearts bearing CBA APCs are rejected by CBA recipients, despite a modest prolongation in survival. The goal of this study was to characterize the cellular infiltrate in acutely rejecting chimeric BALB/c hearts to determine the allorecognition pathway(s) responsible.
Methods: Chimeric BALB/c hearts were created via CBA->BALB/c bone marrow transplantation. Control or chimeric hearts were transplanted heterotopically into naive CBA recipients. Immunohistochemisty (IHC) was performed using a standard avidin biotin complex immunoperoxidase technique on frozen sections obtained from rejected hearts. Antibodies against CD4, CD8, CD11b (macrophages[Mo]), CD11c (dendritic cells[DC]) and CD45R/B220 (B cells) were used. One frozen section from each case was stained with hematoxylin and eosin to grade the rejection.
Results: As in previous studies, APC replacement prolonged graft survival, but did not prevent rejection. All specimens showed acute cellular rejection

Table 1

with no difference in ISHLT grade between groups. Cellular infiltrates in both groups were predominantly effector CD8+ T cells and CD11b+Mo. Chimeric hearts showed an increase in CD11c+ let DC and CD45R/B220+ B cells and CD4+T cells (p=.01, .03, and .05 respectively, Mann-Whitney U Test).

Table 2

Conclusion: Chimeric hearts showed a different pattern of cellular rejection with increased numbers of recipient-type APCs (both B cells and DC) and CD4+ T cells. This supports the hypothesis that heart depleted of donor-type APCs are rejected by the indirect allorecognition pathway.

AM Krasinskas, SH Popma, SD Eiref, AD McLean, JS Moore, RH Hruban, BR Rosengard, University of Pennsylvania Health System, Philadelphia, PA and The Johns Hopkins Medical Institutions, Baltimore, MD.

Previous Page Table Of Contents Next Page